IL-15 has innate anti-tumor activity independent of NK and CD8 T cells
- PMID: 20538758
- DOI: 10.1189/jlb.0909648
IL-15 has innate anti-tumor activity independent of NK and CD8 T cells
Abstract
The innate immune system is crucial for host defense and immunosurveillance against pathogens and tumor cells. IL-15 is a pleiotropic cytokine with important effects on cells of the innate and adaptive immune systems. The NK cell- and CD8(+) T cell-mediated functions of IL-15 against tumor cells have been well documented. However, it has not been established whether IL-15 has innate anti-tumor functions independent of these cells. Here, we explored the innate anti-tumor potential of IL-15 using a B16F10 melanoma tumor model. IL-15tg mice exhibited significantly more resistance to tumor growth and metastasis compared to B6 mice, and to IL-15(-/-) mice, which exhibited increased susceptibility to B16F10 challenge. In vivo depletion of NK cells and CD8(+) T cells abrogated the innate resistance to B16F10 cells in B6 but not in IL-15tg mice. In addition, lung macrophages from IL-15tg mice produced significantly higher levels of NO and IL-12 compared with macrophages from B6 or IL-15(-/-) mice. To examine whether IL-15 has innate anti-tumor activity independent of NK cells and CD8(+) T cells, we developed Ad-Op-hIL-15; this resulted in significantly higher levels of biologically active hIL-15. Delivery of Ad-Op-hIL-15 into RAG-2(-/-)/gamma(c)(-/-) mice significantly suppressed tumor burden in the lungs compared with the control adenovirus vector. Our results show that IL-15 can have innate anti-tumor activity independent of NK cells and CD8(+) T cells and the common gamma(c)R.
Similar articles
-
In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.Exp Dermatol. 2004 Oct;13(10):613-20. doi: 10.1111/j.0906-6705.2004.00198.x. Exp Dermatol. 2004. PMID: 15447721
-
Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma.J Immunol. 2010 Aug 1;185(3):1404-11. doi: 10.4049/jimmunol.1000850. Epub 2010 Jul 7. J Immunol. 2010. PMID: 20610645
-
NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.J Virol. 2005 Apr;79(7):4470-8. doi: 10.1128/JVI.79.7.4470-4478.2005. J Virol. 2005. PMID: 15767447 Free PMC article.
-
IL-15: targeting CD8+ T cells for immunotherapy.Cytotherapy. 2005;7(1):23-35. doi: 10.1080/14653240510018037. Cytotherapy. 2005. PMID: 16040381 Review.
-
Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection.Cytokine Growth Factor Rev. 2010 Oct;21(5):365-79. doi: 10.1016/j.cytogfr.2010.08.002. Epub 2010 Sep 25. Cytokine Growth Factor Rev. 2010. PMID: 20870448 Review.
Cited by
-
Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.Blood Adv. 2023 Feb 14;7(3):384-394. doi: 10.1182/bloodadvances.2021006440. Blood Adv. 2023. PMID: 35475910 Free PMC article.
-
Interleukin-15 treatment induces weight loss independent of lymphocytes.PLoS One. 2012;7(6):e39553. doi: 10.1371/journal.pone.0039553. Epub 2012 Jun 29. PLoS One. 2012. PMID: 22768089 Free PMC article.
-
Delivery of interleukin-15 to B16 melanoma by electroporation leads to tumor regression and long-term survival.Technol Cancer Res Treat. 2014 Dec;13(6):551-60. doi: 10.7785/tcrtexpress.2013.600252. Epub 2013 Aug 31. Technol Cancer Res Treat. 2014. PMID: 24000979 Free PMC article.
-
Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells.Cell Biosci. 2020 Oct 27;10:124. doi: 10.1186/s13578-020-00485-1. eCollection 2020. Cell Biosci. 2020. PMID: 33133514 Free PMC article.
-
Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.Tumour Biol. 2015 Jun;36(6):4535-43. doi: 10.1007/s13277-015-3098-7. Epub 2015 Jan 28. Tumour Biol. 2015. PMID: 25627006
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous